Ligand earns Buy rating from Stifel for its royalty-based funding model and biotech partnerships amid strong revenue and earnings growth.

Cysteinyl leukotrienes (CysLTs) are potent bronchoconstrictors, playing pivotal roles in inflammatory diseases. These lipid ...

Fintel reports that on April 10, 2025, Stifel initiated coverage of Ligand Pharmaceuticals (NasdaqGM:LGND) with a Buy ...